Pfizer (PFE) Restructuring Costs (2009 - 2026)

Pfizer has disclosed Restructuring Costs across 18 years of filings, most recently posting $49.0 million for Q1 2026.

• In Q1 2026, Restructuring Costs fell 92.77% year-over-year to $49.0 million; the TTM figure through Mar 2026 stood at $978.0 million (down 53.54% YoY), while the FY2025 annual figure was $1.6 billion, down 21.99% from the prior year.
• Restructuring Costs declined to $49.0 million in Q1 2026, from $766.0 million in the prior quarter.
• Over the last five years, Restructuring Costs for PFE reached as high as $1.6 billion in Q4 2023 and fell as low as -$74.0 million in Q2 2025.
• The 5-year median for Restructuring Costs is $189.0 million (2022), against an average of $365.4 million.
• Annual changes were most pronounced in 2022 — Restructuring Costs surged 19000.0% — and 2023, when it tumbled 122.92%.
• A 5-year view of Restructuring Costs shows it stood at $177.0 million in 2022, then surged by 798.87% to $1.6 billion in 2023, then tumbled by 80.33% to $313.0 million in 2024, then soared by 144.73% to $766.0 million in 2025, then plunged by 93.6% to $49.0 million in 2026.
• According to Business Quant data, Restructuring Costs over the past three periods registered $49.0 million, $766.0 million, and $237.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.